iPierian is a biotechnology company targeting secreted Tau for treatment of Alzheimer’s disease and other Tauopathies. The company’s lead drug candidate (IPN007) is a monoclonal antibody targeting a novel form of secreted Tau that is differentially regulated in Alzheimer’s disease patients, designed to slow the spread of Tau throughout the brain and therefore inhibit the associated disease progression.
Looking for a particular iPierian employee's phone or email?
The iPierian annual revenue was $11.8 million in 2026.
1 people are employed at iPierian.
iPierian is based in South San Francisco, California.
The NAICS codes for iPierian are [32, 325, 3254].
The SIC codes for iPierian are [28, 283].